Can a new combo drug tame childhood leukemia that Won't quit?

NCT ID NCT07770698

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is investigating whether a new drug called sonrotoclax, when combined with other anti-cancer medicines, is safe and effective for children and adolescents with acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL) that has returned or not responded to treatment. The study will test different doses to find the best one and will monitor how the body processes the drug. The goal is to see if the combination can reduce or eliminate leukemia cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sonrotoclax (BGB-11417) combined with azacitidine, inotuzumab ozogamicin, and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for children with hard-to-treat leukemias, potentially improving remission rates.
What could go wrong
This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The drug combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.